On Biology
Nisreen Al-Moghrabi
Nisreen Al-Moghrabi is the head of the Cancer Epigenetics section in the department of Molecular Oncology at King Faisal Specialist Hospital and Research Center. For the last 10 years, Dr. Al-Moghrabi has been focusing on investigating the possible use of white blood cells aberrant DNA promoter methylation of different cancer suppressor genes, in addition to circulating microRNAs, as potential biomarkers for the early prediction of cancer predisposition. She has also been investigating the epigenetic therapeutic effects of natural compounds on cancer.
How early can breast or ovarian cancer risk be predicted? Transmission of epigenetic changes to BRCA1 and MGMT genes
It is well known that mutations in the BRCA1 gene is implicated in breast and ovarian cancer and that these mutations can be inherited. This study examines is whether epigenetic changes to this gene, and the less understood MGMT gene, can be passed from mother to daughter.
Photo by Praveenpaavni
The incidence of breast and ovarian cancers and mortality due to these cancers in women worldwide is increasing where about 1.7 million new cases were diagnosed worldwide in 2012. This increase in cancer rates carries tremendous socio-economic, emotional, and public health implications. A key factor to the successful treatment of these cancers is early detection and improving prevention which can aided by the identification of biomarkers that can predict the susceptibility to these cancers. Consequently, this will reduce both the cost of treatment and the rate of mortality and morbidity.
No hay comentarios:
Publicar un comentario